EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Evolving standards and future directions for systemic therapies in cervical cancer

Daniel Jia Ming Ang iD, Jack Junjie Chan iD

Journal of Gynecologic Oncology · 2024 · 35 (2)

DOI: 10.3802/jgo.2024.35.e65 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Daniel Jia Ming Ang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, National Cancer Centre Singapore, Singapore. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several groundbreaking clinical trials with the potential to transform the management paradigm of both locally advanced and persistent, recurrent, or metastatic cervical cancers have been presented in 2023. This review describes the reported data from INTERLACE and KEYNOTE-A18 in the locally advanced setting, as well as BEATcc, innovaTV 301 and DESTINY-PanTumor02 for advanced disease. The practice implications of their positive results are interpreted in the context of global health considerations, and updated treatment algorithms are proposed. Furthermore, emerging trends in drug development for cervical cancer are discussed. As the routine use of immune checkpoint inhibitors (ICIs) for curative and palliative indications increases in the foreseeable future, patients whose cervical cancers which persist, relapse or progress after prior ICI exposure will represent an area of unmet clinical need and form the key target population for next-generation trials. Future research will help shape oncologists' approaches in the optimal selection, sequencing and re-treatment or rechallenge of immuno-oncology agents and/or antibody-drug conjugates in women with cervical cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsHumansFemaleImmunotherapyNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Adoptive ImmunotherapyCervical CancerChemoradiotherapyImmune Checkpoint InhibitorsImmunoconjugates

Autor:innen und Institutionen

  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
  • Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore. jack.chan@duke-nus.edu.sg.

ORCID-Profile: Daniel Jia Ming Ang, Jack Junjie Chan

Zitieren

APA

Ang, D. J. M., & Chan, J. J. (2024). Evolving standards and future directions for systemic therapies in cervical cancer. Journal of Gynecologic Oncology, 35(2). https://doi.org/10.3802/jgo.2024.35.e65

Vancouver

Ang DJM, Chan JJ. Evolving standards and future directions for systemic therapies in cervical cancer. Journal of Gynecologic Oncology. 2024;35(2). doi:10.3802/jgo.2024.35.e65

BibTeX
@article{Ang2024,
  author = {Ang, Daniel Jia Ming and Chan, Jack Junjie},
  title = {Evolving standards and future directions for systemic therapies in cervical cancer},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  volume = {35},
  number = {2},
  doi = {10.3802/jgo.2024.35.e65}
}
Kostenlos starten →